268 related articles for article (PubMed ID: 23255309)
1. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
[TBL] [Abstract][Full Text] [Related]
2. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
3. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.
Sequeiros IM; Jarad N
Chron Respir Dis; 2012 Feb; 9(1):9-16. PubMed ID: 22308550
[TBL] [Abstract][Full Text] [Related]
7. Health insurance and use of recommended routine care in adults with cystic fibrosis.
Li SS; Hayes D; Tobias JD; Morgan WJ; Tumin D
Clin Respir J; 2018 May; 12(5):1981-1988. PubMed ID: 29356436
[TBL] [Abstract][Full Text] [Related]
8. Geographic variations in cystic fibrosis: An analysis of the U.S. CF Foundation Registry.
Kopp BT; Nicholson L; Paul G; Tobias J; Ramanathan C; Hayes D
Pediatr Pulmonol; 2015 Aug; 50(8):754-62. PubMed ID: 25825016
[TBL] [Abstract][Full Text] [Related]
9. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
10. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
11. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
12. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
13. Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers.
Glauser TA; Nevins PH; Williamson JC; Abdolrasulnia M; Salinas GD; Zhang J; Debonnett L; Riekert KA
Pediatr Pulmonol; 2012 May; 47(5):434-40. PubMed ID: 22495970
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
[TBL] [Abstract][Full Text] [Related]
15. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.
Nasr SZ; Chou W; Villa KF; Chang E; Broder MS
J Med Econ; 2013; 16(6):801-8. PubMed ID: 23506540
[TBL] [Abstract][Full Text] [Related]
16. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
[TBL] [Abstract][Full Text] [Related]
18. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
